India Unveils BIRSA-101: The First Indigenous Gene Therapy for Sickle Cell Disease
Table of Contents
Source: Indian express
Relevance: GS-III – Science & Technology; Biotechnology;
Key Concepts for Prelims and Mains:
For Prelims:
- Sickle Cell Disease (SCD), HBB Gene Mutation, Sickle Cell Trait (SCT), CRISPR / enFnCas9, BIRSA-101 Gene Therapy
For Mains:
- Atmanirbhar Bharat in Biotechnology, Low-Cost Gene Therapy Model, Tribal-Centric Public Health Approach,Ethical Issues in Gene Editing, Genomic Medicine Infrastructure
Why in News?
India has unveiled BIRSA-101, its first indigenous CRISPR gene therapy for Sickle Cell Disease, marking a major step toward Atmanirbhar Bharat and the goal of a Sickle-Cell-Free India by 2047.
About Sickle Cell Disease (SCD)
- Sickle Cell Disease (SCD) is an inherited haemoglobin disorder caused by a mutation in the HBB gene.
- The mutation produces abnormal haemoglobin S, making red blood cells rigid, sticky, and sickle-shaped.
- Deformed cells have reduced oxygen-carrying capacity and block small blood vessels.
The distorted cells block blood vessels, resulting in:
- Chronic and acute pain crises,
- Anaemia,
- Organ damage,
- High risk of infections, and
- Life-threatening complications such as stroke.
SCD is most widespread in populations of African, Mediterranean, Middle Eastern, and Indian ancestry, with a particularly high burden among Indian tribal groups.
People who carry only one copy of the mutated gene have Sickle Cell Trait (SCT)—largely asymptomatic but capable of transmitting the mutation to offspring.
What is BIRSA-101?
BIRSA-101 is India’s first home-grown gene-editing therapy, named after Birsa Munda, honouring his legacy and recognising the high disease burden among tribal communities.
Key Features
- Completely indigenous CRISPR platform (enFnCas9) created at CSIR-IGIB.
- Works like “precise genetic surgery”, correcting the defective gene responsible for SCD.
- Designed as a one-time curative infusion, enabling the body to produce normal haemoglobin thereafter.
- Cost expected to be a fraction of global gene therapies (which cost ₹20–25 crore / USD 2–3 million).
A phase I clinical trial is already being prepared by IGIB in collaboration with AIIMS. SII will scale the therapy for phase II and III trials and mass production.
How Does BIRSA-101 Work?
Unlike global therapies such as Casgevy, which increase foetal haemoglobin to compensate for defective adult haemoglobin, BIRSA-101 uses CRISPR to directly correct the underlying mutation in the HBB gene.
This method:
- Addresses the root cause of the disease,
- Minimises reliance on lifelong interventions,
- Is safer due to high specificity and reduced risk of off-target genetic edits.
This platform will also be used to develop therapy for thalassaemia, another hereditary blood disorder.
Significance of the Indigenous CRISPR Platform
1. Atmanirbhar Bharat in Frontier Technologies
India becomes one of the few nations developing its own gene-editing tool, reducing dependency on expensive patented systems.
2. Global Cost Reduction
Gene therapies costing more than USD 3 million abroad will become accessible and affordable for Indian patients.
3. Tribal-Centric Public Health Intervention
SCD disproportionately affects tribal regions across central India. BIRSA-101 directly supports the government’s mission to eliminate SCD by 2047.
4. Strengthening India’s Genomic Medicine Ecosystem
The collaboration between CSIR-IGIB and Serum Institute replicates India’s successful vaccine development model witnessed during COVID-19.
Government Push and Institutional Collaboration
Union Minister Dr. Jitendra Singh highlighted BIRSA-101 as a turning point in India’s genomic medicine landscape, emphasising:
- “India is no longer just adopting global technologies; we are creating them.”
- Strong synergy between scientific institutions and the private sector is crucial for scaling biotech innovations.
A formal technology transfer agreement between IGIB and SII ensures:
- Large-scale production,
- Global-standard manufacturing,
- Affordable access, especially for underserved tribal communities.
Government Initiatives for Sickle Cell Disease (SCD)
India has adopted a multi-layered strategy to combat Sickle Cell Disease, combining public health interventions, genomic research, regulatory frameworks, and welfare measures.
1. National Sickle Cell Anaemia Elimination Mission (2023–2047)
The Government launched this mission to transform SCD care through comprehensive screening, counselling, and public awareness. It aims to eliminate SCD as a public health problem by 2047, with special focus on tribal-dominated districts.
Under the Mission, CSIR is advancing indigenous gene-editing therapies as a long-term curative solution.
2. National Health Mission (NHM), 2013
NHM provides the overarching public health platform for early detection and management of hereditary disorders, including SCD. It supports:
- Screening and awareness at community and school levels,
- Provision of essential medicines like hydroxyurea, and
- Integration of SCD management into primary healthcare services.
3. National Guidelines for Stem Cell Research (2017)
These guidelines regulate the use of stem cell technologies.
- Commercial stem cell therapies are prohibited, except Bone Marrow Transplantation (BMT)—the only approved curative option for SCD.
- Gene editing in stem cells is allowed only for in-vitro research, preventing unregulated clinical deployment.
4. National Guidelines for Gene Therapy Product Development & Clinical Trials (2019)
These guidelines establish an ethical and regulatory pathway for developing and testing gene therapies for genetic diseases.
India has also funded a five-year national project to develop CRISPR-based therapies for SCD, enabling indigenous platforms like enFnCas9.
5. State-Level Missions (Example: Madhya Pradesh Haemoglobinopathy Mission)
States with high SCD burden have created specialised missions focusing on:
- Universal screening of schoolchildren and tribal communities,
- Counselling of carriers,
- Strengthening district-level treatment facilities.
6. Rights of Persons with Disabilities (RPwD) Act, 2016
SCD is officially recognised as one of the 21 disabilities, ensuring:
- Reservations in education (5%) and government jobs (4%),
- Priority in government housing and land allotments,
- Free compulsory education for children (6–18 years) with benchmark disability,
- Social welfare and financial support for families affected by SCD.
Challenges & Concerns
- Off-target effects
Potential risk of unintended DNA edits. - Long-term safety monitoring
Requires multi-year observation. - Infrastructure gaps
Most tribal districts lack gene therapy facilities. - Regulatory complexity
India needs robust clinical gene editing guidelines. - Ethical issues
Germline vs somatic editing debates. - High initial costs before scaling
Even at low cost, therapy may need subsidies.
Conclusion
BIRSA-101 marks a historic leap for India in genomic medicine, public health, and technological self-reliance.By creating an indigenous CRISPR platform and developing a curative therapy for Sickle Cell Disease, India is not merely catching up with the world—it is leading in affordable, cutting-edge gene therapeutics.If clinical trials confirm safety and efficacy, BIRSA-101 could become a global model for low-cost gene therapy, transforming the lives of millions living with hereditary blood disorders and advancing India’s vision of a Sickle-Cell-Free Nation by 2047.
UPSC PYQ
Q. Consider the following statements in the context of interventions being undertaken under Anaemia Mukt Bharat: (UPSC 2023)
- It provides prophylactic calcium supplementation for pre-school children, adolescents and pregnant women.
- It runs a campaign for delayed cord clamping at the time of childbirth.
- It provides for periodic deworming to children and adolescents.
- It addresses non-nutritional causes of anaemia in endemic pockets with special focus on malaria, hemoglobinopathies and fluorosis.
How many of the statements given above are correct?
a) Only one
b) Only two
c) Only three
d) All four
Correct Answer: (c) Only three
CARE MCQ
Q. Consider the following statements regarding Sickle Cell Disease (SCD):
- SCD occurs when a person inherits two copies of the mutated haemoglobin S (HBB) gene.
- Individuals with one normal haemoglobin gene and one haemoglobin S gene develop sickle-cell trait (SCT).
- People with sickle-cell trait usually remain asymptomatic but can transmit the gene to their children.
How many of the above statements are correct?
(a) Only one
(b) Only two
(c) All three
(d) None
Correct Answer: (c) All three